Prioritisation of HIV, Hepatitis C and Tuberculosis medicines for in-licensing by the Medicines Patent Pool.
Comments are welcome and encouraged. Please send an email to firstname.lastname@example.org with subject line “Comments on the 2019 Prioritisation Report”.
The MPP focuses on increasing access to HIV, hepatitis C and tuberculosis medicines. The organisation’s current remit also includes patented essential medicines with high medical value, with a priority given to small molecules, and those with strong potential for future inclusion on the World Health Organization Model List of Essential Medicines (EML).
Since our creation in 2010, we have published a list of priority HIV treatments for our licensing programme. In 2017, we expanded our evaluation to include important treatments for hepatitis C, and in 2018 we included tuberculosis treatments in our prioritisation work. Our method for prioritising HIV, hepatitis C and tuberculosis treatments, developed with the support of a broad range of experts, is based on four criteria:
In 2019, the MPP published a prioritisation framework that outlines a precise methodology for assessing candidate medicines that could play a major role in the MPP’s expanded mandate into new disease therapies beyond HIV, hepatitis C and tuberculosis.
Target medicines may include those already in the market as well as investigational candidates. The focus is on medicines that are not yet licensed to the MPP.
The 2019 Prioritisation Report includes one HIV and one TB compounds that could improve standard of care for people living in developing countries. It also includes three HIV and three TB compounds in watchlists.
|Cabotegravir long-acting injectable|
In addition, the following products have been included in MPP watchlists:
|Islatravir (MK-8591, EFdA)|
Finally, the following three products have been identified as ARVs to be further monitored:
|Other HIV products to monitor|
|Rilpivirine long-acting injectable|
The status of negotiations on priority products will be updated on a quarterly basis in line with MPP’s Transparency Policy.